Equities Analysts Issue Forecasts for SPRY FY2028 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Research analysts at Leerink Partnrs dropped their FY2028 EPS estimates for ARS Pharmaceuticals in a research note issued to investors on Thursday, March 20th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will post earnings of $1.57 per share for the year, down from their prior forecast of $1.70. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings results on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.56. The company had revenue of $86.58 million during the quarter, compared to analyst estimates of $15.46 million.

SPRY has been the subject of a number of other reports. Leerink Partners lifted their target price on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Oppenheimer started coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an “outperform” rating and a $40.00 price objective on the stock. William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Raymond James upped their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. Finally, Scotiabank started coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $31.00.

ARS Pharmaceuticals Stock Performance

SPRY stock opened at $12.89 on Monday. The stock has a market cap of $1.25 billion, a P/E ratio of -25.27 and a beta of 1.03. The firm has a 50 day simple moving average of $12.10 and a 200 day simple moving average of $13.06. ARS Pharmaceuticals has a 52 week low of $7.55 and a 52 week high of $18.51.

Institutional Trading of ARS Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Bernard Wealth Management Corp. acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at approximately $27,000. KLP Kapitalforvaltning AS acquired a new position in shares of ARS Pharmaceuticals during the 4th quarter worth $73,000. BNP Paribas Financial Markets acquired a new stake in ARS Pharmaceuticals in the fourth quarter valued at about $75,000. Ball & Co Wealth Management Inc. acquired a new position in ARS Pharmaceuticals during the fourth quarter worth about $105,000. Finally, Compass Capital Corp MA ADV acquired a new position in ARS Pharmaceuticals during the 4th quarter worth approximately $106,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Insider Activity

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00. Following the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,334,840.60. This trade represents a 19.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eric Karas sold 10,000 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the sale, the insider now directly owns 7,696 shares in the company, valued at $107,744. This represents a 56.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 159,600 shares of company stock valued at $1,866,516. 40.10% of the stock is currently owned by insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.